BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 25986389)

  • 1. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study.
    Shaheen FA; Kurpad R; Al-Sayyari AA; Souqiyyeh MZ; Aljubori H; El Baz T; Kashif W; Tuganbekova S; Kabulbayev K; Jarraya F; Nafar M
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
    Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL; Worcester EM; Coe FL; Sprague SM
    J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 - 5 non-dialysis patients?
    Dincer MT; Ozcan SG; Alagoz S; Karaca C; Gulcicek SH; Trabulus S; Pekpak M; Seyahi N
    Clin Nephrol; 2022 Nov; 98(5):239-246. PubMed ID: 35979902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
    Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient.
    Heaf JG
    Perit Dial Int; 2015 Nov; 35(6):640-4. PubMed ID: 26702005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
    Minutolo R; Locatelli F; Gallieni M; Bonofiglio R; Fuiano G; Oldrizzi L; Conte G; De Nicola L; Mangione F; Esposito P; Dal Canton A;
    Nephrol Dial Transplant; 2013 Dec; 28(12):3035-45. PubMed ID: 24145459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.